Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Triheptanoin · Dojolvi, UX-007

Other · developed by Ultragenyx Pharm

Approved FDA, Jun 2020
RARE Developer
3 Registered trials

What is Triheptanoin?

Triheptanoin is a medium-chain triglyceride made of three odd-chain 7-carbon fatty acids (heptanoate). It provides calories and fatty acids that bypass long-chain fatty acid oxidation enzyme deficiencies for energy production, and is studied in long-chain fatty acid oxidation disorders, including carnitine palmitoyltransferase, VLCAD, LCHAD, trifunctional protein and CACT deficiencies, as well as Huntington disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Dojolvi, UX-007, C7
Drug type
Other
Pathways
fatty acid oxidation, energy production
Therapy area
Neurology, Psychiatry
Developer
Ultragenyx Pharm Inc (RARE)
FDA status
Approved as Dojolvi (June 30, 2020), NDA213687 · FDA label
UNII
2P6O7CFW5K

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 10, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05933200 Phase 3 Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Active not recruiting RARE
NCT02453061 Phase 2 Huntington Disease Completed RARE
NCT02214160 Phase 2 Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency Completed RARE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)Carnitine Palmitoyltransferase (CPT I or CPT II) DeficiencyCarnitine-acylcarnitine Translocase (CACT) DeficiencyHuntington DiseaseTrifunctional Protein (TFP) DeficiencyVery Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency

More from Ultragenyx Pharm

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RARE page.

Follow RARE, the company behind Triheptanoin

See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RARE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.